Unhealthy Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with Hepatitis C

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Muga, Roberto ^a   Sanvisens, Arantza ^a   Fuster, Daniel ^a,b   Tor, Jordi ^a   Martínez, Elisenda ^a   Pérez Hoyos, Santiago ^c   Muñoz, Alvaro ^d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BILIRUBIN; CHOLESTEROL;

ADULT; ALBUMIN BLOOD LEVEL; ALCOHOLISM; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG ABUSE; FEMALE; FIB 4 SCORE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RISK ASSESSMENT; SCORING SYSTEM; SEROLOGY;

ADULT; ALCOHOL DRINKING; DRUG USERS; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; RISK FACTORS;

EID: 84867301760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046810     Document Type: Article

References (34)

1. Thomas DL, Seeff LB (2005) Natural history of hepatitis C. Clin Liver Dis 9: 383,98, vi DOI:10.1016/j.cld.2005.05.003.
2. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, et al. (2006) Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 44: S19-S24 DOI:10.1016/j.jhep.2005.11.009.
3. Davis GL, Lau JY, (1997) Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 26: 122S-127S DOI:10.1002/hep.510260721.
4. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, et al. (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34: 730-739.
5. Sulkowski MS, Thomas DL, (2003) Hepatitis C in the HIV-Infected Person. Ann Intern Med 138: 197-207.
6. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054-1058 DOI:10.1002/hep.510300409.
7. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, et al. (2001) Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34: 283-287 DOI:10.1053/jhep.2001.26517.
8. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, et al. (2003) Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362: 1708-1713 DOI:10.1016/S0140-6736(03)14844-1.
9. Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, et al. (2011) HIV mono-infection is associated with FIB-4- A noninvasive index of liver fibrosis- in women. Clin Infect Dis 52: 674-680 DOI:10.1093/cid/ciq199.
10. Chaudhry AA, Sulkowski MS, Chander G, Moore RD, (2009) Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med 10: 133-142 DOI:10.1111/j.1468-1293.2008.00662.x.
11. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, et al. (2002) Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 36: S161-S172 DOI:10.1053/jhep.2002.36989.
12. Sulkowski MS, Thomas DL, (2005) Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis 40 (Suppl 5): S263-S269 DOI:10.1086/427440.
13. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D, (2003) Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36: 97-100 DOI:10.1086/344907.
14. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, et al. (2006) Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 11: 131-142.
15. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, et al. (2004) Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99: 271-279.
16. Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, et al. (2009) Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 16: 513-518 DOI:10.1111/j.1365-2893.2009.01103.x.
17. Pohl A, Behling C, Oliver D, Kilani M, Monson P, et al. (2001) Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 96: 3142-3146 DOI:10.1111/j.1572-0241.2001.05268.x.
18. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43: 1317-1325 DOI:10.1002/hep.21178.
19. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, et al. (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32-36 DOI:10.1002/hep.21669.
20. Sebastiani G, Vario A, Guido M, Alberti A, (2008) Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 15: 212-218 DOI:10.1111/j.1365-2893.2007.00932.x.
21. Vallet-Pichard A, (2008) Predictive value of FIB-4 versus Fibrotest, APRI, FIBROINDEX and FORNS to noninvasively estimate fibrosis in hepatitis C. Hepatology. 47: 763.
22. Nunes D, Fleming C, Offner G, Craven D, Fix O, et al. (2010) Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 105: 1346-1353 DOI:10.1038/ajg.2009.746.
23. Sanvisens A, Fuster D, Serra I, Tor J, Tural C, et al. (2011) Estimated Liver Fibrosis and its Impact on All-Cause Mortality of HCV-Monoinfected and HCV/HIV-Coinfected Drug Users. Curr HIV Res 9: 256-262.
24. Saitz R, (2005) Clinical practice. Unhealthy alcohol use. N Engl J Med 352: 596-607 DOI:10.1056/NEJMcp042262.
25. National Institute in Alcohol Abuse and Alcoholism (1995) The Physician's guide to helping patients with alcohol problems. USDHHS NIH Publ 95-3769.
26. Muga R, Roca J, Egea JM, Tor J, Sirera G, et al. (2000) Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr 2000 23: 332-338.
27. Hutchinson SJ, Bird SM, Goldberg DJ, (2005) Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 3: 1150-1159.
28. Siu L, Foont J, Wands JR, (2009) Hepatitis C virus and alcohol. Semin Liver Dis 29: 188-199 DOI:10.1055/s-0029-1214374.
29. Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, et al. (2003) Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 10: 118-125.
30. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, Torre-Cisneros J, Garcia-Garcia JA, et al. (2006) Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20: 49-57.
31. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD, (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283: 74-80.
32. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, et al. (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284: 450-456.
33. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, et al. (2009) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50: 1030-7 DOI:10.1002/hep.23219.
34. Inglesby TV, Rai R, Astemborski J, Gruskin L, Nelson KE, et al. (1999) A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 29: 590-596 DOI:10.1002/hep.510290219.